Bain Capital Public Equity Management Ii, LLC Atea Pharmaceuticals, Inc. Transaction History

Bain Capital Public Equity Management Ii, LLC

$2.33 Billion
Q1 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$19.22 - $59.08 $16.3 Million - $50.1 Million	-847,208 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $10.4 Million - $22.1 Million	-250,000 Reduced 22.79%	847,208 $52.3 Million
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $28.9 Million - $45.8 Million	1,097,208 New	1,097,208 $42.3 Million

Others Institutions Holding AVIR

# of Institutions

119

Shares Held

49.6M

Call Options Held

108K

Put Options Held

327K

Black Rock Inc. New York, NY

9.24M
Shares

$30.6 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.15M
Shares

$20.3 Million
0.71% of portfolio
Bml Capital Management, LLC Zionsville, IN

5.54M
Shares

$18.3 Million
14.98% of portfolio
Vanguard Group Inc Valley Forge, PA

4.72M
Shares

$15.6 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

4.08M
Shares

$13.5 Million
2.01% of portfolio

View Full List

About Atea Pharmaceuticals, Inc.

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $276M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

More about AVIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Account